Journal Browser

► Journal Browser

Special Issue Editor

Prof. Dr. Nicolas Bonadies

E-Mail Website
Guest Editor

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Interests: myeloid neoplasms; Myelodysplastic Syndromes; precision medicine; health care research

Special Issue Information

Dear Colleagues,

Incident cases of patients with myelodysplastic syndromes and clonal hematopoiesis are on the rise, with a relevant impact on health care systems. This can be accredited to aging of the general population, improved cancer survivorship, but also an increase of sensitivity in detecting clonality in patients with unclear cytopenia. Due to the heterogeneity of the presentations and the mainly elderly population with many comorbid conditions, the management plan for diagnosis and treatment can be complex and resource-intensive. Therefore, the investigation of appropriate health care provided to patients with MDS and clonal hematopoiesis is of emerging interest for our health care systems.

With this Special Issue of IJERPH, we would like to increase awareness on these emerging hemato-oncological conditions and report the most recent data on relevant population epidemiology, health service research, real world data processing, diagnostic and treatment approaches, fields of further investigations, and methods to increase appropriateness and quality of care in every day clinical practice. Reports can involve analyses of primary data from population-based cancer registries, real world data from cohorts, computational modelling, and clinical research involving health care providers.

Guest Editors

Prof. Dr. Nicolas Bonadies
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

myelodysplastic syndromes
health service research
epidemiology
real world data
clinical data processing
clinical development cycles

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

18 pages, 321 KiB

Open AccessArticle

Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement

by Ioannis Chanias, C. Matthias Wilk, Rudolf Benz, Michael Daskalakis, Georg Stüssi, Adrian Schmidt, Ulrike Bacher, Nicolas Bonadies and on behalf of the Swiss MDS Study Group

Int. J. Environ. Res. Public Health 2020, 17(24), 9562; https://doi.org/10.3390/ijerph17249562 - 21 Dec 2020

Cited by 3 | Viewed by 1927

Abstract

The impact on health care of patients with myelodysplastic syndromes (MDS) is continuously rising. To investigate the perception of hemato-oncologists concerning the recommended MDS patient care in Switzerland, we conducted a web-based survey on diagnosis, risk-stratification and treatment. 43/309 physicians (13.9%) replied to 135 questions that were based on current guidelines between 3/2017 and 2/2018. Only questions with feedback-rates >50% were further analysed and ratios >90% defined “high agreement”, 70–90% “agreement”, 30–70% “insufficient agreement” and <30% “disagreement”. For diagnosis, we found insufficient agreement on using flow-cytometry, classifying MDS precursor conditions, performing treatment response assessment after hypomethylating agents (HMA) and evaluating patients with suspected germ-line predisposition. For risk-stratification, we identified agreement on using IPSS-R but insufficient agreement for IPSS and patient-based assessments. For treatment, we observed disagreement on performing primary infectious prophylaxis in neutropenia but agreement on using only darbepoetin alfa in anaemic, lower-risk MDS patients. For thrombopoietin receptor agonists, insufficient agreement was found for the indication, preferred agent and triggering platelet count. Insufficient agreement was also found for immunosuppressive treatment in hypoplastic MDS and HMA dose adjustments. In conclusion, we identified areas for improvement in MDS patient care, in need of further clinical trials, information, and guiding documents. Full article

(This article belongs to the Special Issue Providing Appropriate Health Care in Patients with Myelodysplastic Syndromes and Clonal Hematopoiesis)

Review

Jump to: Research

10 pages, 598 KiB

Open AccessReview

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?

by Annika Kasprzak, Jennifer Kaivers, Kathrin Nachtkamp, Rainer Haas, Guido Kobbe, Norbert Gattermann and Ulrich Germing

Int. J. Environ. Res. Public Health 2021, 18(14), 7629; https://doi.org/10.3390/ijerph18147629 - 18 Jul 2021

Cited by 3 | Viewed by 2304

Abstract

The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS. Full article

(This article belongs to the Special Issue Providing Appropriate Health Care in Patients with Myelodysplastic Syndromes and Clonal Hematopoiesis)

► Show Figures